NCT02433678View on ClinicalTrials.gov

An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

November 30, 2018

Conditions
Type 2 Diabetes
Interventions
DRUG

dapagliflozin

SGLT-2 inhibitor for the treatment of type 2 diabetes

DRUG

Placebo

Trial Locations (1)

14215

ECMC Ambulatory Center, 3rd Floor, Buffalo

Sponsors

Collaborators (1)

Kaleida Health
All Listed Sponsors
collaborator

Kaleida Health

OTHER

lead

University at Buffalo

OTHER

NCT02433678 - An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin | Biotech Hunter | Biotech Hunter